Physician profile
Michael W Engelman
NPI 1891758165
$1,190.06
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $45.07 · 2021: $183 · 2022: $395 · 2023: $408 · 2024: $18.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.93 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $160.10 | 2019-2023 | |
| Dermavant Sciences, INC. | $136.61 | 2023 | Vtama |
| Amgen INC. | $97.41 | 2021-2023 | Otezla |
| Janssen Biotech, INC. | $95.61 | 2021-2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $69.13 | 2021-2023 | Dupixent |
| Leo Pharma INC. | $68.31 | 2021-2022 | |
| Incyte Corporation | $49.93 | 2022-2023 | Opzelura |
| Ucb, INC. | $35.81 | 2019-2021 | |
| Galderma Laboratories, L.P. | $34.23 | 2022-2023 | Epsolay, Aklief, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.61 | 2023 | Sotyktu |
| Pfizer INC. | $19.64 | 2022 | |
| Genzyme Corporation | $17.26 | 2020 | |
| Almirall LLC | $17.26 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.67 | 2020 | |
| Biofrontera INC. | $14.50 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $13.45 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Engelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.